Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Kay

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
Nature Reviews. Genetics|April 7, 2011
State-of-the-art gene-based therapies: the road aheadMark A Kay
Nature Biotechnology|October 9, 2007
AAV vectors and tumorigenicityMark A Kay
Human Gene Therapy|January 24, 2008
Prime time for small RNA-based therapeuticsMark A Kay
Molecular Therapy. Nucleic Acids|December 6, 2024
Ruvkun and Ambros recognized for miRNAsMark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2015
Selecting the Best AAV Capsid for Human StudiesMark A Kay
Blood|May 16, 2002
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivoAnja Ehrhardt, Mark A Kay
The Journal of Clinical Investigation|December 7, 2007
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?Dirk Grimm, Mark A Kay
Science (New York, N.Y.)|March 7, 2015
RNA interference. Drugging RNAiDirk Haussecker, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2010
miR-122 continues to blaze the trail for microRNA therapeuticsDirk Haussecker, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2025
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapyFrancesco Puzzo, Mark A Kay
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
Nature Reviews. Genetics|April 7, 2011
State-of-the-art gene-based therapies: the road aheadMark A Kay
Nature Biotechnology|October 9, 2007
AAV vectors and tumorigenicityMark A Kay
Human Gene Therapy|January 24, 2008
Prime time for small RNA-based therapeuticsMark A Kay
Molecular Therapy. Nucleic Acids|December 6, 2024
Ruvkun and Ambros recognized for miRNAsMark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2015
Selecting the Best AAV Capsid for Human StudiesMark A Kay
Blood|May 16, 2002
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivoAnja Ehrhardt, Mark A Kay
The Journal of Clinical Investigation|December 7, 2007
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?Dirk Grimm, Mark A Kay
Science (New York, N.Y.)|March 7, 2015
RNA interference. Drugging RNAiDirk Haussecker, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2010
miR-122 continues to blaze the trail for microRNA therapeuticsDirk Haussecker, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2025
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapyFrancesco Puzzo, Mark A Kay
Pageof 20